Ani pharmaceuticals reports record fourth quarter financial results and achieves full year 2022 revenue milestone; initiates 2023 guidance

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (nasdaq: anip) (ani or the company) today announced business highlights and financial results for the three and 12 months ended december 31, 2022. “2022 was a transformative year for ani, taking us past critical inflection points for our two key growth drivers – the launch of cortrophin gel, our foundational rare disease asset, and investment in our generics business.
ANIP Ratings Summary
ANIP Quant Ranking